# BIOPLEX 2200 EBV IgM KIT, CALIBRATORS, AND CONTROLS 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

<table><tr><td>510(k) Number</td><td>510(k) Summary Report Date</td></tr><tr><td>k062213</td><td>December 7, 2006</td></tr></table>

# MANUFACTURER INFORMATION

<table><tr><td rowspan=1 colspan=2>Manufacturer</td></tr><tr><td rowspan=1 colspan=1>Manufacturer Address</td><td rowspan=1 colspan=1>Bio-Rad Laboratories, Inc.Clinical Systems Division4000 Alfred Nobel DriveHercules, CA 94547</td></tr><tr><td rowspan=1 colspan=1>Telephone</td><td rowspan=1 colspan=1>(510) 724-7000</td></tr><tr><td rowspan=1 colspan=1>Establishment Registration No.</td><td rowspan=1 colspan=1>2915274</td></tr><tr><td rowspan=1 colspan=1>Owner / Operator</td><td rowspan=1 colspan=1>Bio-Rad Laboratories, Inc.4000 Alfred Nobel DriveHercules, CA 94547</td></tr><tr><td rowspan=1 colspan=1>Owner / Operator No.</td><td rowspan=1 colspan=1>9929003</td></tr><tr><td rowspan=1 colspan=2>Official Correspondent for the BioPlex 2200 EBV IgM</td></tr><tr><td rowspan=1 colspan=1>Official Correspondent Address</td><td rowspan=1 colspan=1>Bio-Rad Laboratories6565 185th Ave NERedmond, WA 98052</td></tr><tr><td rowspan=1 colspan=1>Telephone</td><td rowspan=1 colspan=1>425-881-8300</td></tr><tr><td rowspan=1 colspan=1>Establishment Registration No.</td><td rowspan=1 colspan=1>3022521</td></tr><tr><td rowspan=1 colspan=1>Owner / Operator</td><td rowspan=1 colspan=1>Bio-Rad Laboratories6565 185t Ave NERedmond, WA 98052</td></tr><tr><td rowspan=1 colspan=1>Official Correspondent</td><td rowspan=1 colspan=1>Mr. Christopher Bentsen</td></tr><tr><td rowspan=1 colspan=1>Telephone</td><td rowspan=1 colspan=1>(425) 498-1709</td></tr><tr><td rowspan=1 colspan=1>Fax</td><td rowspan=1 colspan=1>(425) 498-1651</td></tr></table>

# CLASSIFICATION INFORMATION

<table><tr><td rowspan=1 colspan=1>Classification Name</td><td rowspan=1 colspan=1>Epstein Barr Virus, Other (LSE)</td></tr><tr><td rowspan=1 colspan=1>Common Name:</td><td rowspan=1 colspan=1>Multi-Analyte Detection System EBV IgM</td></tr><tr><td rowspan=1 colspan=1>Product Trade Name</td><td rowspan=1 colspan=1>BioPlex 2200 EBV IgM on the BioPlex 2200 Multi-AnalyteDetection SystemBioPlex 2200 EBV IgG Control SetBioPlex 2200 EBV IgG Calibrator Set</td></tr><tr><td rowspan=1 colspan=1>Device Class</td><td rowspan=1 colspan=1>Class I</td></tr><tr><td rowspan=1 colspan=1>Classification Panel</td><td rowspan=1 colspan=1>Microbiology</td></tr><tr><td rowspan=1 colspan=1>Regulation Number</td><td rowspan=1 colspan=1>866.3235</td></tr></table>

# LEGALLY MARKETED EQUIVALENT (SE) DEVICES

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>BioPlex2200 EBVIgG Analyte</td><td rowspan=1 colspan=1>Comparative FDA ClearedPREDICATE DEVICE</td><td rowspan=1 colspan=1>510(k)Number</td><td rowspan=1 colspan=1>DecisionDate</td></tr><tr><td rowspan=1 colspan=1>1.</td><td rowspan=1 colspan=1>EBV VCA</td><td rowspan=1 colspan=1>Diasorin EBV VCA IgM Capture EIA</td><td rowspan=1 colspan=1>946157</td><td rowspan=1 colspan=1>6/7/95</td></tr><tr><td rowspan=1 colspan=1>2.</td><td rowspan=1 colspan=1>Heterophile</td><td rowspan=1 colspan=1>Wampole Monolatex</td><td rowspan=1 colspan=1>862008</td><td rowspan=1 colspan=1>7/03/86</td></tr></table>

# DEVICE DESCRIPTION

The BioPlex 2200 EBV IgM kit uses multiplex flow immunoassay, a methodology that greatly resembles traditional ElA, but permits simultaneous detection and identification of many antibodies in a single tube. Two (2) different populations of dyed beads are coated with proteins associated with infectious mononucleosis. One (1) is coated with an E. coli derived recombinant fusion protein, EBV VCA $\mathsf { p } 1 8$ (40kD), and the other is coated with horse erythrocyte stromal extract (heterophile antigen). The BioPlex 2200 System combines an aliquot of patient sample, sample diluent containing goat anti-human IgG, and bead reagent into a reaction vessel. The mixture is incubated at $3 7 ^ { \circ } \mathsf { C }$ . After a wash cycle, anti-human IgM antibody, conjugated to phycoerythrin (PE), is added to the dyed beads and this mixture is incubated at $3 7 ^ { \circ } \mathsf { C }$ The excess conjugate is removed in another wash cycle, and the beads are re-suspended in wash buffer. The bead mixture then passes through the detector. The identity of the dyed beads is determined by the fluorescence of the dyes, and the amount of antibody captured by the antigen is determined by the fluorescence of the attached PE.

Three additional dyed beads, an Internal Standard Bead (ISB), a Serum Verification Bead (SVB), and a Reagent Blank Bead (RBB), are present in each reaction mixture to verify detector response, the addition of serum or plasma to the reaction vessel, and the absence of significant non-specific binding in serum or plasma respectively. The instrument is calibrated using a set of two (2) distinct calibrator vials, supplied separately by Bio-Rad Laboratories. A combination of two () vials representing two (2) different antibody concentrations is used for calibration.The result for each of these antibodies is expressed as an antibody index (Al).

# KIT COMPONENTS

EBV IgM Reagent Pack (Catalog No. 665-1350). The reagent pack contains supplies sufficient for 100 tests.

<table><tr><td rowspan=1 colspan=1>Vial</td><td rowspan=1 colspan=1>Description</td></tr><tr><td rowspan=1 colspan=1>Bead Set</td><td rowspan=1 colspan=1>One (1) 10 mL vial, containing 2 different populations of dyed beads coatedwith affinity-purified E. coli derived recombinant protein to EBV VCA p18(40kD), and Heterophile antigen (horse erythrocyte stromal extract); anInternal Standard (ISB), a Serum Verification (SVB), and a Reagent Blank(RBB); with Glycerol and protein stabilizers (bovine) in a MOPS (3-[N-Morpholino] propanesulfonic acid) buffer. ProClin® 300 (0.3%) and sodiumazide (&lt;0.1%) as preservatives.</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>One (1) 5 mL vial, containing donkey anti-human IgM/phycoerythrinconjugate and murine monoclonal anti-human FXill / phycoerythrinconjugate, in a phosphate buffer. Proclin® 300 (0.3%) and Sodium azide(0.1%) as preservatives.</td></tr><tr><td rowspan=1 colspan=1>Sample Diluent</td><td rowspan=1 colspan=1>One (1) 10 mL vial, containing goat anti-human IgG and protein stabilizers(bovine and murine) in a triethanolamine buffer. Proclin® 300 (0.3%) andSodium azide (0.1%) as preservatives.</td></tr></table>

ADDITIONAL REQUIRED ITEMS, AVAILABLE FROM BIO-RAD   

<table><tr><td rowspan=1 colspan=1>Catalog #</td><td rowspan=1 colspan=1>Description</td></tr><tr><td rowspan=1 colspan=1>663-1300</td><td rowspan=1 colspan=1>BioPlex 2200 EBV IgM Calibrator Set: Two (2) 500 µL vials, containing EBVVCA and heterophile antibodies, in a human serum matrix made fromdefibrinated plasma. ProClin® 300 (0.3%) as a preservative for allcalibrators.</td></tr><tr><td rowspan=1 colspan=1>663-1330</td><td rowspan=1 colspan=1>BioPlex 2200 EBV IgM Control Set: Two (2) 1.5 mL vials of Positive Controlcontaining EBV VCA and heterophile antibodies, in a human serum matrixmade from defibrinated plasma; and two (2) 1.5 mL vials of NegativeControl in a human serum matrix made from defibrinated plasma. ProClin®300 (0.3%) as a preservative for all controls.</td></tr><tr><td rowspan=1 colspan=1>660-0817</td><td rowspan=1 colspan=1>BioPlex 2200 System Sheath Fluid: Two (2) 4 L bottles containingPhosphate Buffered Saline (PBS). Proclin® 300 (0.3%) and Sodium azide(0.1%) as preservatives.</td></tr><tr><td rowspan=1 colspan=1>660-0818</td><td rowspan=1 colspan=1>BioPlex 2200 System Wash Solution: One (1) 10 L bottle containingPhosphate Buffered Saline (PBS) and Tween 20. Proclin® 300 (0.3%) andSodium azide (0.1%) as preservatives.</td></tr><tr><td rowspan=1 colspan=1>660-0000</td><td rowspan=1 colspan=1>BioPlex 2200 Instrument and Software.</td></tr></table>

# INTENDED USE / INDICATIONS FOR USE

The BioPlex 2200 EBV IgM kit is a multiplex flow immunoassay intended for the qualitative detection of two (2) separate analytes; Epstein-Barr Virus Viral Capsid Antigen (EBV VCA) IgM antibodies and Heterophile antibodies in human serum. The test system can be used in conjunction with the BioPlex 2200 EBV IgG kit as an aid in the laboratory diagnosis of infectious mononucleosis (IM).

The EBV IgM kit is intended for use with the Bio-Rad BioPlex 2200 System.

Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients, cord blood, neonatal specimens, or infants. Assay performance characteristics have not been established for the diagnosis of nasopharyngeal carcinoma, Burkitt's lymphoma, and other EBV-associated lymphomas.

# BioPlex 2200 EBV IgM Calibrator Set

The BioPlex 2200 EBV IgM Calibrator Set is intended for the calibration of the BioPlex 2200 EBV IgM Reagent Pack.

# BioPlex 2200 EBV IgM Control Set

The BioPlex 2200 EBV IgM Control Set is intended for use as an assayed quality control to monitor the overall performance of the BioPlex 2200 Instrument and BioPlex 2200 EBV IgM Reagent Pack in the clinical laboratory. The performance of the BioPlex 2200 EBV IgM Control Set has not been established with any other EBV assays.

# TECHNOLOGICAL CHARACTERISTICS

The following tables summarize similarities and differences between the BioPlex 2200 EBV IgG Kit, Calibrators, and Controls and the predicate devices used in comparative studies with the BioPlex 2200 EBV IgG Kit.

A. BioPlex 2200 EBV IgM Assay: EBV VCA

Table 1: Similarities between reagents and materials   

<table><tr><td rowspan=1 colspan=1>Similarities betweenComponents /Materials</td><td rowspan=1 colspan=1>BioPlex 2200 EBV IgM Kit</td><td rowspan=1 colspan=1>Predicate EBV VCA IgMReverse Capture ElA</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Wash Buffer, Sample Diluent</td><td rowspan=1 colspan=1>Wash Buffer, Sample Diluent</td></tr><tr><td rowspan=1 colspan=1>Calibrator(s)</td><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>Calibrators</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Negative Control and Multi-Analyte Positive Control (EBVVCA, EBV NA-1, and EBV EA-D)</td><td rowspan=1 colspan=1>Negative Control, Low PositiveControl, and High PositiveControl</td></tr></table>

Table 2: Similarities between reagents with regard to function and use   

<table><tr><td>Similarities between Function and Use</td><td>BioPlex 2200 EBV IgM Kit</td><td>Predicate EBV VCA IgM Reverse Capture EIA</td></tr><tr><td>Intended Use</td><td>Qualitative detection of IgM antibodies in human serum to EBV Viral Capsid Antigen (VCA).</td><td>antibodies in human serum to EBV Viral Capsid Antigen (VCA).</td></tr><tr><td>Matrices Serum</td><td></td><td>Serum</td></tr></table>

Table 3: Differences between reagents and materials   

<table><tr><td rowspan=1 colspan=1>Differences betweenComponents /Materials</td><td rowspan=1 colspan=1>BioPlex 2200 EBV IgM Kit</td><td rowspan=1 colspan=1>Predicate EBV VCA IgMReverse Capture EIA</td></tr><tr><td rowspan=1 colspan=1>Solid Phase</td><td rowspan=1 colspan=1>Bead reagent - dyed antigencoated beads</td><td rowspan=1 colspan=1>96 well microplate - antigencoated microwells</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Conjugate (Anti-human IgM /Phycoerythrin)</td><td rowspan=1 colspan=1>Enzyme Tracer (Rat monoclonalanti-p18 conjugated with horse-radish peroxidase), TracerDiluent, Reconstitution Solution,Chromogen / Substrate (TMB),Stop Solution</td></tr><tr><td rowspan=1 colspan=1>Sheath Fluid</td><td rowspan=1 colspan=1>Sheath Fluid is used to suspendthe bead reagent and introduce itinto the detector.</td><td rowspan=1 colspan=1>Not similar; not utilized in EIA&#x27;s.</td></tr></table>

Table 4: Differences between reagents with regard to function and use   

<table><tr><td rowspan=1 colspan=1>Differences betweenFunction and Use</td><td rowspan=1 colspan=1>BioPlex 2200 EBV IgM Kit</td><td rowspan=1 colspan=1>Predicate EBV VCA IgMReverse Capture EIA</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Qualitative detection of IgMantibodies in human serum toEBV Viral Capsid Antigen (VCA).</td><td rowspan=1 colspan=1>Semi-quantitative detection ofIgM antibodies in human serumto EBV Viral Capsid Antigen(VCA).</td></tr><tr><td rowspan=1 colspan=1>Analyte Detection</td><td rowspan=1 colspan=1>Multi-Analyte Detection (humanIgG antibodies to EBV VCA, EBVNA-1, and EBV EA-D)</td><td rowspan=1 colspan=1>Single Analyte Detection(human IgM antibody to EBVViral Capsid Antigen)</td></tr></table>

# B. BioPlex 2200 EBV IgM Assay: Heterophile

Table 5: Similarities between reagents and materials   

<table><tr><td>Similarities between Components / Materials</td><td>BioPlex 2200 EBV IgM Kit</td><td>Predicate MONO-LATEX Latex Agglutination Test</td></tr><tr><td>Controls</td><td>Negative Control and Multi- Analyte Positive Control (EBV VCA IgM and Heterophile)</td><td>Negative Control and Positive Control</td></tr></table>

Table 6: Similarities between reagents with regard to function and use   

<table><tr><td rowspan=1 colspan=1>Similarities betweenComponents /Materials</td><td rowspan=1 colspan=1>BioPlex 2200 EBV IgM Kit</td><td rowspan=1 colspan=1>Predicate MONO-LATEX LatexAgglutination Test</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Qualitative detection ofheterophile antibodies</td><td rowspan=1 colspan=1>Qualitative detection ofheterophile antibodies</td></tr><tr><td rowspan=1 colspan=1>Matrices</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum</td></tr></table>

Table 7: Differences between reagents and materials   

<table><tr><td rowspan=1 colspan=1>Differences betweenComponents /Materials</td><td rowspan=1 colspan=1>BioPlex 2200 EBV IgM Kit</td><td rowspan=1 colspan=1>Predicate MONO-LATEX LatexAgglutination Test</td></tr><tr><td rowspan=1 colspan=1>Solid Phase</td><td rowspan=1 colspan=1>Bead reagent - dyed antigencoated beads</td><td rowspan=1 colspan=1>Latex reagent - suspension ofmononucleosis antigensensitized latex particles</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>Sample Diluent, Conjugate, WashBuffer, Sheath Fluid</td><td rowspan=1 colspan=1>Not similar; these reagents notutilized in latex agglutinationtests.</td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>Not similar; not utilized in latexagglutination tests.</td></tr></table>

Table 8: Differences between reagents with regard to function and use   

<table><tr><td rowspan=1 colspan=1>Differences betweenComponents /Materials</td><td rowspan=1 colspan=1>BioPlex 2200 EBV IgM Kit</td><td rowspan=1 colspan=1>Predicate MONO-LATEX LatexAgglutination Test</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Qualitative detection ofheterophile antibodies.</td><td rowspan=1 colspan=1>Semi-quantitative detection ofheterophile antibodies.</td></tr><tr><td rowspan=1 colspan=1>Matrices</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Plasma</td></tr><tr><td rowspan=1 colspan=1>Analyte Detection</td><td rowspan=1 colspan=1>Multi-Analyte Detection (humanEBV VCA IgM and heterophileantibodies)</td><td rowspan=1 colspan=1>Single Analyte Detection(human heterophile antibodies)</td></tr></table>

# PERFORMANCE SUMMARY

# A. Expected Values

Expected values for the EBV IgM kit are presented by age and gender in the following tables for serum samples from unselected hospitalized pediatric and adult patients $( N = 3 0 2 )$ and patients for which an EBV test was ordered $( N = 6 1 9 )$ . A total of 303 serum samples from unselected hospitalized pediatric and adult patients and a total of 621 serum samples from patients for which an EBV test was ordered were tested. One (1) sample from the unselected hospitalized population, and two (2) samples from the patients for which an EBV test was ordered population were excluded due to RBB analysis error messages during BioPlex 2200 EBV IgM testing. For all analytes, results of $\mathtt { \le 0 . 8 }$ Al are negative, 0.9 and 1.0 Al are equivocal, and ${ \gtrsim } 1 . 1$ Al are reported as positive.

Table 9: Hospitalized Patient Samples: EBV VCA IgM   

<table><tr><td rowspan=3 colspan=1>Age</td><td rowspan=3 colspan=1>Geixler</td><td rowspan=1 colspan=6>BioPlex 2200 EBV VCA IgM</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=2>Positive</td><td rowspan=1 colspan=2>Equivocal</td><td rowspan=1 colspan=2>Negative</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>.6</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=2 colspan=1>&lt; 5 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>11%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>8996</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>95%</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=2 colspan=1>5-12 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>9%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>91%</td><td rowspan=1 colspan=1>22</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3%</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>94%</td><td rowspan=1 colspan=1>34</td></tr><tr><td rowspan=2 colspan=1>13-20 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>14%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3%</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>83%</td><td rowspan=1 colspan=1>35</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>046</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>7%</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>93%</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=2 colspan=1>21-30 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=2 colspan=1>31-40 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=2 colspan=1>41-50 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8%0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>92%</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>14%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>86%</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=2 colspan=1>51-60 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>23</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5%</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>95%</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=2 colspan=1>61-70 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>09</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>096</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=2 colspan=1>71-80 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>9%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>91%</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%6</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=2 colspan=1>81-90 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=2 colspan=1>91-100 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>5%</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1%</td><td rowspan=1 colspan=1>283</td><td rowspan=1 colspan=1>94%</td><td rowspan=1 colspan=1>302</td></tr></table>

Table 10: Hospitalized Patient Samples: Heterophile   

<table><tr><td rowspan=3 colspan=1>Age</td><td rowspan=3 colspan=1>Gender</td><td rowspan=1 colspan=6>BioPlex 2200 Heterophile</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=2>Positive</td><td rowspan=1 colspan=2>Equivocal</td><td rowspan=1 colspan=2>Negative</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=2 colspan=1>&lt; 5 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>96%</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>20</td></tr><tr><td rowspan=2 colspan=1>5-12 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>22</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>34</td></tr><tr><td rowspan=2 colspan=1>13-20 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>35</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=2 colspan=1>21-30 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=2 colspan=1>31-40 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>096</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=2 colspan=1>41-50 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>01%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=2 colspan=1>51-60 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>23</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=2 colspan=1>61-70 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=2 colspan=1>71-80 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%0</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>09%</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=2 colspan=1>81-90 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>11</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=2 colspan=1>91-100 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>99%</td><td rowspan=1 colspan=1>302</td></tr></table>

Table 11: Samples from Patients for which an EBV Test was Ordered: EBV VCA IgM   

<table><tr><td rowspan=3 colspan=1>Aye</td><td rowspan=3 colspan=1>Gender</td><td rowspan=1 colspan=6>BioPlex 2200 EBV VCA IgM</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=2>Positive</td><td rowspan=1 colspan=2>Equivocal</td><td rowspan=1 colspan=2>Negative</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%6</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>0%%$</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=2 colspan=1>&lt; 5 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>10%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>90%</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>18%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>82%</td><td rowspan=1 colspan=1>33</td></tr><tr><td rowspan=2 colspan=1>5-12 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>15%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2%</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>84%</td><td rowspan=1 colspan=1>62</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>10%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2%</td><td rowspan=1 colspan=1>55</td><td rowspan=1 colspan=1>899%</td><td rowspan=1 colspan=1>62</td></tr><tr><td rowspan=2 colspan=1>13-20 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>22%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3%</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>76%</td><td rowspan=1 colspan=1>78</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>26%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3%</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>71%</td><td rowspan=1 colspan=1>38</td></tr><tr><td rowspan=2 colspan=1>21-30 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>11%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2%0</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>87%</td><td rowspan=1 colspan=1>46</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>21%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3%</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>76%</td><td rowspan=1 colspan=1>33</td></tr><tr><td rowspan=2 colspan=1>31-40 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>10%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2%</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>88%</td><td rowspan=1 colspan=1>52</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>96%</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=2 colspan=1>41-50 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>9%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3%</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>88%</td><td rowspan=1 colspan=1>34</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>13%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3%</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>84%</td><td rowspan=1 colspan=1>31</td></tr><tr><td rowspan=2 colspan=1>51-60 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>15%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>81%</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>8%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4%</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>88%</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=2 colspan=1>61-70 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>8%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>92%</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=2 colspan=1>71-80 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=2 colspan=1>81-90 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=2 colspan=1>91-100 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1>13%</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>2%</td><td rowspan=1 colspan=1>524</td><td rowspan=1 colspan=1>85%</td><td rowspan=1 colspan=1>619</td></tr></table>

Table 12: Samples from Patients for which an EBV Test was Ordered: Heterophile   

<table><tr><td rowspan=3 colspan=1>Age</td><td rowspan=3 colspan=1>Gerder</td><td rowspan=1 colspan=6>BioPlex 2200 Heterophile</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=2>Positive</td><td rowspan=1 colspan=2>Equivocal</td><td rowspan=1 colspan=2>Negative</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>0.</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=2 colspan=1>&lt; 5 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>33</td></tr><tr><td rowspan=2 colspan=1>5-12 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>540</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>096</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>95%</td><td rowspan=1 colspan=1>62</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>5%0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>95%</td><td rowspan=1 colspan=1>62</td></tr><tr><td rowspan=2 colspan=1>13-20 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>10%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1%</td><td rowspan=1 colspan=1>69</td><td rowspan=1 colspan=1>88%</td><td rowspan=1 colspan=1>78</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>18%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3%</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>79%</td><td rowspan=1 colspan=1>38</td></tr><tr><td rowspan=2 colspan=1>21-30 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>49%</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>96%</td><td rowspan=1 colspan=1>46</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1240</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>88%</td><td rowspan=1 colspan=1>33</td></tr><tr><td rowspan=2 colspan=1>31-40 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>52</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>92%</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=2 colspan=1>41-50 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>09%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>34</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>31</td></tr><tr><td rowspan=2 colspan=1>51-60 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>26</td></tr><tr><td rowspan=2 colspan=1>61-70 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>O</td><td rowspan=1 colspan=1>0%0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>13</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=2 colspan=1>71-80 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>M$</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=2 colspan=1>81-90 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=2 colspan=1>91-100 years of age</td><td rowspan=1 colspan=1>F</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>M</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>04%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>4%</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>1%</td><td rowspan=1 colspan=1>588</td><td rowspan=1 colspan=1>95%</td><td rowspan=1 colspan=1>619</td></tr></table>

The distribution of BioPlex 2200 EBV VCA IgM and Heterophile AI values for serum samples from adult and pediatric unselected hospitalized patients and from patients for which an EBV test was ordered are presented in the following histograms.

![](images/e338780825a6e5e3ddea1dd9edd67c45900a78a094ca9f0c1b9f3b00f2f887c3.jpg)  
Figure 1: Hospitalized Patient Samples: EBV VCA IgM

![](images/41f54468b6ab15cc642d0a8997d93c6744e134f3ebe09dca305832fc744735e5.jpg)  
Figure 2: Hospitalized Patient Samples: Heterophile

![](images/34a0f3952806c5b2b43c375c82a366486da6e32139e47740bcde0e867614a52e.jpg)  
Figure 3. Samples from Patients for which an EBV Test was Ordered: EBV VCA IgM

![](images/823ef099f4b9d15d1f33e73c92c1d02a8c530068d70209eaad557d288c53ce5f.jpg)  
Figure 4. Samples from Patients for which an EBV Test was Ordered: Heterophile

# B. Reproducibility Studies

A reproducibility panel, consisting of six (6) panel members was prepared by Bio-Rad Laboratories. Two (2) of the six (6) panel members had high levels of the antibodies contained in the BioPlex 2200 EBV IgM kit (EBV VCA IgM and Heterophile) and two (2) of the six (6) panel members had antibody levels near the cutoff both prepared from positive patient samples. Two (2) of the six (6) panel members were negative (one high negative and one low negative) for both o the analytes. In addition, a positive control (antibody positive for both analytes) and a negative control (antibody negative for both analytes) were also tested. Reproducibility testing was performed at each of three (3) US testing facilities on a total of three (3) lots of the EBV IgM kit, three (3) lots of the EBV IgM Calibrator Set and three (3) lots of the EBV IgM Control Set. The panels were provided to each of the testing sites. Each of the six (6) panel members and positive and negative controls was tested in quadruple $( x 4 )$ on each day for three (3) days at each of three (3) US testing facilities using one (1) lot of EBV IgM kit, one (1) lot of EBV IgM Calibrator Set and one (1) lot of EBV IgM Control Set (4 times x 3 days $\textsf { x 3 }$ sites $= 3 6$ replicates per panel member and controls). The data were analyzed for intra-assay and inter-assay reproducibility according to the principles described in the Clinical Laboratory Standards Institute guidance EP5-A2, revised November 2004 and ISO/TR 22971:2205. The standard deviation (SD) and percent coefficient of variation $( \% C V )$ were calculated. Positive results can be found in Tables 12 and 13.

Table 12: Reproducibility Results; BioPlex 2200 EBV VCA IgM   

<table><tr><td rowspan=2 colspan=1>EBV VCA IgMPanel Members</td><td rowspan=2 colspan=1>SampleN</td><td rowspan=2 colspan=1>GrandMeanAI</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Site*</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td></tr><tr><td rowspan=1 colspan=1>High Positive 1</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.9%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>4.5%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>3.8%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>8.4%</td></tr><tr><td rowspan=1 colspan=1>High Positive 2</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>3.5%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.8%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>7.1%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=1 colspan=1>35^*</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.6%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>8.3%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 2</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.8%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>4.8%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>7.9%</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.5%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>15.9%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>17.2%</td></tr></table>

\*Between site variance includes between lot variance. $^ { \star \star } 1$ replicate missing due to insuffcient sample volume.

Table 13: Reproducibility Results; BioPlex 2200 Heterophile   

<table><tr><td rowspan=2 colspan=1>HeterophilePanel Members</td><td rowspan=2 colspan=1>SampleN</td><td rowspan=2 colspan=1>GrandMeanAI</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Betweenl-Day</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Between-Site*</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%oCV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>High Positive 1</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.2%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.1%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>7.8%</td></tr><tr><td rowspan=1 colspan=1>High Positive 2</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.5%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=1 colspan=1>35**</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.5%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 2</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.6%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>7.4%</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.9%</td></tr></table>

\*Between site variance includes between lot variance. pliate issin  sufficit smple o

# C. Precision Studies

A precision panel, consisting of six (6) panel members was prepared by Bio-Rad Laboratories. Two (2) of the six (6) panel members had high levels of the antibodies contained in the BioPlex 2200 EBV IgG kit EBV IgM kit (EBV VCA IgM and Heterophile) and two (2) of the six (6) panel members had antibody levels near the cutoff, both prepared from positive patient samples. Two ()f the six (6) panel members were negative (one high negative and one low negative) for both of the analytes.

Precision testing was performed at Bio-Rad Laboratories on one lot of the EBV IgM kit, one lot of the EBV IgM Calibrator Set and one lot of the EBV IgM Control Set. Each of the six (6) panel members was tested in duplicate $\{ \times 2 \}$ on two (2) runs per day for ten (10) days using one (1) lot o EBV IgM kit, one (1) lot of EBV IgM Calibrator Set and one (1) lot of EBV IgM Control Set (2 times $\times 2$ runs x 10 days $= 4 0$ replicates per panel member). The data were analyzed for intraassay and inter-assay precision according to the principles described in the Clinical Laboratory Standards Institute guidance EP5-A2, revised November 2004 and ISO/TR 22971:2205. The standard deviation (SD) and percent coefficient of variation $( \% C V )$ were calculated.

Table 14: Precision Results; BioPlex 2200 EBV VCA IgM   

<table><tr><td rowspan=2 colspan=1>EBV VCA IgMPanel Members</td><td rowspan=2 colspan=1>SampleN*</td><td rowspan=2 colspan=1>AIMean</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td></tr><tr><td rowspan=1 colspan=1>High Positive 1</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>8.8%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>6.6%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>11.2%</td></tr><tr><td rowspan=1 colspan=1>High Positive 2</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>5.6%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>6.9%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>9.1%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>6.5%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>4.3%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>7.8%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 2</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>4.8%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>7.1%</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>6.4%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>7.0%</td></tr><tr><td rowspan=1 colspan=1>Low Negative</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td></tr></table>

Table 15: Precision Results; BioPlex 2200 Heterophile   

<table><tr><td rowspan=2 colspan=1>HeterophilePanel Members</td><td rowspan=2 colspan=1>SampleN^{</td><td rowspan=2 colspan=1>AIMean</td><td rowspan=1 colspan=2>Within-Run</td><td rowspan=1 colspan=2>Between-Day</td><td rowspan=1 colspan=2>Between-Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>High Positive 1</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>8.6%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>9.5%</td></tr><tr><td rowspan=1 colspan=1>High Positive 2</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>4.7%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>9.9%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>5.3%</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>12.2%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 1</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>9.0%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>10.5%</td></tr><tr><td rowspan=1 colspan=1>Low Positive 2</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>3.9%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>4.6%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>7.5%</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>9.6%</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>7.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>4.6%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>8.4%</td></tr><tr><td rowspan=1 colspan=1>Low Negative</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0%</td></tr></table>

# D.Comparative Testing

Typical Antibody Response Characterization

The following table demonstrates a generally accepted algorithm for classifying patients into an EBV status via serologic profiles. EBV status can be applied to any patient based on results of standard tests. In acute IM, both EBV IgM and EBV IgG antibodies to viral capsid antigen (VCA) rise rapidly. EBV VCA IgM antibody disappears over about four weeks. Heterophile antibody, which is of the IgM class, appears only during acute infection and fades rapidly over about four weeks. EBV EA-D IgG antibody shows a transient raise during acute infection, undetectable after 3 - 6 months. EBV NA-1 IgG antibody usually appears 3 months after initial infection and remains for life.

Table 16: Serological Status   

<table><tr><td rowspan=1 colspan=1>EBV Serological Status</td><td rowspan=1 colspan=1>EBV NA-1 IgG</td><td rowspan=1 colspan=1>EBV VCA IgG</td><td rowspan=1 colspan=1>EBV EA-D IgG</td><td rowspan=1 colspan=1>EBV VCAIgM</td><td rowspan=1 colspan=1>Heterophile Antibody</td></tr><tr><td rowspan=8 colspan=1>Primary Acute</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Pos(+)</td><td rowspan=1 colspan=1>Pos(+</td><td rowspan=1 colspan=1>Pas(+</td><td rowspan=1 colspan=1>Neg (-)</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Pos(+</td><td rowspan=1 colspan=1>Pos(+</td><td rowspan=1 colspan=1>Pos(+)</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Pos{(+$</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Pos(+</td><td rowspan=1 colspan=1>Pas{+</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Pos (+}</td><td rowspan=1 colspan=1>Pos(+</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Pos (+</td><td rowspan=1 colspan=1>Neg (-)</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>Pos (+</td><td rowspan=1 colspan=1>Neg (-)</td></tr><tr><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Pos(+)</td><td rowspan=1 colspan=1>Pos(+)</td><td rowspan=1 colspan=1>Pos1+</td><td rowspan=1 colspan=1>Pos(+)</td></tr><tr><td rowspan=1 colspan=1>Neg (-1</td><td rowspan=1 colspan=1>Pos1+)</td><td rowspan=1 colspan=1>Pos(+</td><td rowspan=1 colspan=1>Neg i-)</td><td rowspan=1 colspan=1>Pos(+)</td></tr><tr><td rowspan=6 colspan=1>Late Acute</td><td rowspan=1 colspan=1>Neg (-1)</td><td rowspan=1 colspan=1>Pos(+}$</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Pos(+</td><td rowspan=1 colspan=1>Neg (-)</td></tr><tr><td rowspan=1 colspan=1>Pas(+)</td><td rowspan=1 colspan=1>Pos(+</td><td rowspan=1 colspan=1>Pos(+}$</td><td rowspan=1 colspan=1>Pos +}</td><td rowspan=1 colspan=1>Pos(+)</td></tr><tr><td rowspan=1 colspan=1>Pas(+</td><td rowspan=1 colspan=1>Pos+$</td><td rowspan=1 colspan=1>Pos(+)</td><td rowspan=1 colspan=1>$Pos(+}$</td><td rowspan=1 colspan=1>Neg (-)</td></tr><tr><td rowspan=1 colspan=1>Pas(+)</td><td rowspan=1 colspan=1>$Pos1+}$</td><td rowspan=1 colspan=1>Neq (-)</td><td rowspan=1 colspan=1>Pos(+</td><td rowspan=1 colspan=1>Pos1+</td></tr><tr><td rowspan=1 colspan=1>Pos(+)</td><td rowspan=1 colspan=1>Pos(+)</td><td rowspan=1 colspan=1>Pos(+</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Neg (-1</td></tr><tr><td rowspan=1 colspan=1>Pos(+)</td><td rowspan=1 colspan=1>Pos(+)</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Pas(+)</td><td rowspan=1 colspan=1>Neg (-)</td></tr><tr><td rowspan=1 colspan=1>Recovering</td><td rowspan=1 colspan=1>Neg (-1</td><td rowspan=1 colspan=1>Pos+)</td><td rowspan=1 colspan=1>Pos(1+</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Neg (-)</td></tr><tr><td rowspan=2 colspan=1>Previous Infection</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Pos+</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Neg (-)</td></tr><tr><td rowspan=1 colspan=1>Pos(+)</td><td rowspan=1 colspan=1>Pos(+</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Neg (-)</td></tr><tr><td rowspan=1 colspan=1>Susceptible</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Neg (-)</td><td rowspan=1 colspan=1>Neg (-)</td></tr></table>

lt serological pattern not identified in Table 16 should be considered inconclusive.

Comparison of BioPlex 2200 EBV IgM kit and Microplate EIA/Agglutination Tests Perormance of the EBV IgM kit was tested against corresponding commercially available microplate ElAagglutination tests. A total of 621 banked serum samples from patients for which an EBV test was ordered were tested at 3 U.S. clinical testing sites. The EBV IgG kit was run in conjunction with the EBV IgM kit to allow for a complete antibody response profile. The characterization by antibody response was not compared with clinical data regarding presence, absence or status of disease. Two (2) samples were excluded due to RBB analysis error messages during BioPlex 2200 EBV IgM testing. One (1) sample was excluded due to RBB analysis error messages during BioPlex 2200 EBV IgG testing. Using Table 16 as a guideline, results were analyzed by BioPlex 2200 EBV IgM analytes and corresponding EBV IgM reference assays according to serological characterization based on reference assay results. For the purpose of percent agreement calculations, BioPlex 2200 EBV IgM equivocal results were assigned to the opposite clinical interpretation than that of the corresponding reference assay result. Results from all sites are shown and summarized in Tables 17 - 20.

Table 17. BioPlex 2200 EBV VCA IgM vs. EIA: Comparison by Serological Pattern Characterization   

<table><tr><td rowspan=5 colspan=1>EBVSerological Status</td><td rowspan=1 colspan=6>Reference EBV VCA IgM Interpretation</td><td rowspan=4 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=3>Positive</td><td rowspan=1 colspan=3>Negative</td></tr><tr><td rowspan=1 colspan=3>BioPlex 2200 EBV VCA IgM</td><td rowspan=1 colspan=3>BioPlex 2200 EBV VCA IgM</td></tr><tr><td rowspan=1 colspan=1>Pas</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=1>Primary Acute</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>31</td></tr><tr><td rowspan=1 colspan=1>Late Acute</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>110</td></tr><tr><td rowspan=1 colspan=1>Recovering</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Previous Infection</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>293</td><td rowspan=1 colspan=1>305</td></tr><tr><td rowspan=1 colspan=1>Susceptible</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>127</td></tr><tr><td rowspan=1 colspan=1>Inconclusive</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>41</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>507</td><td rowspan=1 colspan=1>618</td></tr></table>

Table 18: BioPlex 2200 EBV VCA IgM vs. EIA: Percent Agreement & Confidence Intervals by Serological Pattern Characterization   

<table><tr><td rowspan=1 colspan=1>EBVSerological Status</td><td rowspan=1 colspan=2>Positive Agreement</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=2>Negative Agreement</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Primary Acute</td><td rowspan=1 colspan=1>(30/31)</td><td rowspan=1 colspan=1>96.8%</td><td rowspan=1 colspan=1>83.8 - 99.4%</td><td rowspan=1 colspan=1>(0/0)</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>N/A*</td></tr><tr><td rowspan=1 colspan=1>Late Acute</td><td rowspan=1 colspan=1>(31/48)</td><td rowspan=1 colspan=1>64.6%</td><td rowspan=1 colspan=1>50.4 - 76.6%</td><td rowspan=1 colspan=1>(57/62)</td><td rowspan=1 colspan=1>91.9%</td><td rowspan=1 colspan=1>82.5 - 96.5%</td></tr><tr><td rowspan=1 colspan=1>Recovering</td><td rowspan=1 colspan=1>(0.0)</td><td rowspan=1 colspan=1>NA*</td><td rowspan=1 colspan=1>NA*</td><td rowspan=1 colspan=1>(3/4)</td><td rowspan=1 colspan=1>75.0%</td><td rowspan=1 colspan=1>30.1 - 95.4%</td></tr><tr><td rowspan=1 colspan=1>Previous Infection</td><td rowspan=1 colspan=1>(0/0)</td><td rowspan=1 colspan=1>N^A*</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>(293/305)</td><td rowspan=1 colspan=1>96.1%</td><td rowspan=1 colspan=1>93.2 - 97.7%</td></tr><tr><td rowspan=1 colspan=1>Susceptible</td><td rowspan=1 colspan=1>(0/0)</td><td rowspan=1 colspan=1>NA*</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>(123/127)</td><td rowspan=1 colspan=1>96.9%</td><td rowspan=1 colspan=1>92.2 - 98.8%</td></tr><tr><td rowspan=1 colspan=1>Inconclusive</td><td rowspan=1 colspan=1>(4.4)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>51.0-100%</td><td rowspan=1 colspan=1>(31/37)</td><td rowspan=1 colspan=1>83.8%</td><td rowspan=1 colspan=1>68.9 - 92.3%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>(65/83)</td><td rowspan=1 colspan=1>78.39%</td><td rowspan=1 colspan=1>68.3 - 85.8%</td><td rowspan=1 colspan=1>(507/535)</td><td rowspan=1 colspan=1>94.8%</td><td rowspan=1 colspan=1>92.5 - 96.4%</td></tr></table>

$^ { * } I n$ cases where agreement resulted in (0/0) samples, percent agreement and $9 5 \%$ confidence interval could not be calculated.

Table 19: BioPlex 2200 Heterophile vs. Agglutination Test: Comparison by Serological Pattern Characterization   

<table><tr><td rowspan=5 colspan=1>EBVSerological Status</td><td rowspan=1 colspan=6>Reference Heterophile Interpretation</td><td rowspan=4 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=3>Positive</td><td rowspan=1 colspan=3>Negative</td></tr><tr><td rowspan=1 colspan=3>BioPlex 2200 Heterophile</td><td rowspan=1 colspan=3>BioPlex 2200 Heterophile</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Euv</td><td rowspan=1 colspan=1>Ney</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Ney</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=1>Primary Acute</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>31</td></tr><tr><td rowspan=1 colspan=1>Late Acute</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>104</td><td rowspan=1 colspan=1>110</td></tr><tr><td rowspan=1 colspan=1>Recovering</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4</td></tr><tr><td rowspan=1 colspan=1>Previous Infection</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>302</td><td rowspan=1 colspan=1>305</td></tr><tr><td rowspan=1 colspan=1>Susceptible</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>127</td><td rowspan=1 colspan=1>127</td></tr><tr><td rowspan=1 colspan=1>Inconclusive</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>41</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>561</td><td rowspan=1 colspan=1>618</td></tr></table>

Table 0: BioPlex 2200 Heterophile vs.Agglutination Test Percent Agreement & Confidence Intervals y Serological Pattern Characterization   

<table><tr><td rowspan=1 colspan=1>EBVSerological Status</td><td rowspan=1 colspan=2>Positive Agreement</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=2>Negative Agreement</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Primary Acute</td><td rowspan=1 colspan=1>(16/19)</td><td rowspan=1 colspan=1>84.2%</td><td rowspan=1 colspan=1>62.4 - 94.5%</td><td rowspan=1 colspan=1>(10/12)</td><td rowspan=1 colspan=1>83.3%</td><td rowspan=1 colspan=1>55.2 - 95.3%</td></tr><tr><td rowspan=1 colspan=1>Late Acute</td><td rowspan=1 colspan=1>(3/4)</td><td rowspan=1 colspan=1>75.0%</td><td rowspan=1 colspan=1>30.1 - 95.4%</td><td rowspan=1 colspan=1>(104/106)</td><td rowspan=1 colspan=1>98.1%</td><td rowspan=1 colspan=1>93.4 - 99.5%</td></tr><tr><td rowspan=1 colspan=1>Recovering</td><td rowspan=1 colspan=1>(0/0)</td><td rowspan=1 colspan=1>NVA*</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>(4/4)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>51.0 - 100%</td></tr><tr><td rowspan=1 colspan=1>Previous Infection</td><td rowspan=1 colspan=1>(0/0)</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>NIA*</td><td rowspan=1 colspan=1>(302/305)</td><td rowspan=1 colspan=1>99.0%</td><td rowspan=1 colspan=1>97.1 - 99.7%</td></tr><tr><td rowspan=1 colspan=1>Susceptible</td><td rowspan=1 colspan=1>(0/0)</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>N/A*</td><td rowspan=1 colspan=1>(127/127)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>97.1 - 100%</td></tr><tr><td rowspan=1 colspan=1>Inconclusive</td><td rowspan=1 colspan=1>(4/27)</td><td rowspan=1 colspan=1>14.8%</td><td rowspan=1 colspan=1>5.9 - 32.5%</td><td rowspan=1 colspan=1>(14/14)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>78.5 - 100%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>(23/50)</td><td rowspan=1 colspan=1>46.0%</td><td rowspan=1 colspan=1>33.0 - 59.6%</td><td rowspan=1 colspan=1>(561/568)</td><td rowspan=1 colspan=1>98.8%</td><td rowspan=1 colspan=1>97.5 - 99.4%</td></tr></table>

\*In cases where agreement resulted in $( 0 / 0 )$ samples, percent agreement and $9 5 \%$ confidence interval could not be calculated.

Comparison of BioPlex 2200 EBV IgM kit and Microplate EIA (known VCA IgM positive samples) Performance of the EBV IgM kit was further tested with serum samples that were previously characterized as EBV VCA IgM positive samples by another commercially available IgM EIA. A total of 100 purchased EBV VCA IgM positive samples were tested with the EBV IgM kit against corresponding commercially available microplate ElAagglutination tests at a U.S. clinical testing site. The EBV IgG kit was run in conjunction with the EBV IgM kit to allow for a complete antibody response profile. The characterization by antibody response was not compared with clinical data regarding presence, absence or status of disease. Using Table 16 as a guideline, results were analyzed by BioPlex 2200 EBV IgM analytes and corresponding EBV IgM reference assays according to serological characterization based on reference assay results. For the purpose of percent agreement calculations, BioPlex 2200 EBV IgM equivocal results were assigned to the opposite clinical interpretation than that of the corresponding reference assay result. Results are shown and summarized in Tables 21 - 25.

Table 21: BioPlex 2200 EBV VCA IgM vs. EIA: Comparison by Serological Pattern Characterization   

<table><tr><td rowspan=5 colspan=1>EBV SerologicalStatus</td><td rowspan=1 colspan=6>Reference EBV VCA IgM Interpretation</td><td rowspan=4 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=3>Positive</td><td rowspan=1 colspan=3>Negative</td></tr><tr><td rowspan=1 colspan=3>BioPlex 2200 EBV VCA IgM</td><td rowspan=1 colspan=3>BioPlex 2200 EBV VCA IgM</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=1>Late acute</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr></table>

Table 22: BioPlex 2200 EBV VCA IgM vs. EIA: Percent Agreement & Confidence Intervals by Serological Pattern Characterization   

<table><tr><td rowspan=1 colspan=1>EBV SerologicalStatus</td><td rowspan=1 colspan=2>PositiveAgreement</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=2>NegativeAgreement</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Late acute</td><td rowspan=1 colspan=1>(100/100)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>96.3 - 100%</td><td rowspan=1 colspan=1>(0/0)</td><td rowspan=1 colspan=1>NA*</td><td rowspan=1 colspan=1>NA*</td></tr><tr><td rowspan=1 colspan=1>Overail</td><td rowspan=1 colspan=1>(100/100)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>96.3 - 100%</td><td rowspan=1 colspan=1>(0/0)</td><td rowspan=1 colspan=1>NA*</td><td rowspan=1 colspan=1>NA*</td></tr></table>

\*In cases where agreement resulted in $( 0 / 0 )$ samples, percent agreement and $9 5 \%$ confidence interval could not be calculated.

Table 23: BioPlex 2200 Heterophile vs. Agglutination Test: Comparison by Serological Pattern Characterization   

<table><tr><td rowspan=5 colspan=1>EBV SerologicalStatus</td><td rowspan=1 colspan=6>Reference Heterophile Interpretation</td><td rowspan=4 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=3>Positive</td><td rowspan=1 colspan=3>Negative</td></tr><tr><td rowspan=1 colspan=3>BioPlex 2200 Heterophile</td><td rowspan=1 colspan=3>BioPlex 2200 Heterophile</td></tr><tr><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Ney</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Eqv</td><td rowspan=1 colspan=1>Ney</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=1>Late acute</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td></tr></table>

TabBiex 200 Heterophile .gglutination Test:Percent Agreement &Confidence Intervals Serological Pattern Characterization   

<table><tr><td rowspan=1 colspan=1>EBV SerologicalStatus</td><td rowspan=1 colspan=2>PositiveAgreement</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=2>NegativeAgreement</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Late acute</td><td rowspan=1 colspan=1>(100/100)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>96.3 - 100%</td><td rowspan=1 colspan=1>(0/0)</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>NA*</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>(100/100)</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>96.3 - 100%</td><td rowspan=1 colspan=1>(0/0)</td><td rowspan=1 colspan=1>NA^</td><td rowspan=1 colspan=1>NA*</td></tr></table>

\*In cases where agreement resulted in $_ { \{ 0 / 0 \} }$ samples, percent agreement and $9 5 \%$ confidence interval could not be calculated.

# Comparison of EBV Serological Status

Using Table 16 as a guideline, samples characterized into serological status associated with EBV disease, using the commercially available microplate ElA and agglutination tests, were compared with characterizations using BioPlex 2200 EBV IgG and IgM kits. The BioPlex 2200 EBV IgM kit was run in conjunction with the BioPlex 2200 EBV IgG kit to allow for a complete antibody response profile. The characterization by antibody response was not compared with clinical data regarding presence, absence or status of disease. Results from 618 serum samples tested at 3 U.S. clinical testing sites are shown in Table 25.

Table 25: Comparison of EBV Serological Status   

<table><tr><td rowspan=2 colspan=2>EBV Serological status</td><td rowspan=1 colspan=9>BioPlex 2200 EBV IgG &amp; IgM Profile</td></tr><tr><td rowspan=1 colspan=1>Pne e</td><td rowspan=1 colspan=1>are aee</td><td rowspan=1 colspan=1>Beeed</td><td rowspan=1 colspan=1>Phenoge</td><td rowspan=1 colspan=1>Ss ee</td><td rowspan=1 colspan=1>Tme</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Soos %Areeant</td><td rowspan=1 colspan=1>cm0Cal</td></tr><tr><td rowspan=7 colspan=1>CccAa aee</td><td rowspan=1 colspan=1>Primary Acute</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>96.8%</td><td rowspan=1 colspan=1>83.8 - 99.4%</td></tr><tr><td rowspan=1 colspan=1>Late Acute</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>110</td><td rowspan=1 colspan=1>81.8%</td><td rowspan=1 colspan=1>73.6 - 87.9%</td></tr><tr><td rowspan=1 colspan=1>Recovering</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>75.0%</td><td rowspan=1 colspan=1>30.0 - 95.4%</td></tr><tr><td rowspan=1 colspan=1>Previous infection</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>263</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>305</td><td rowspan=1 colspan=1>86.2%</td><td rowspan=1 colspan=1>81.9 - 89.7%</td></tr><tr><td rowspan=1 colspan=1>Susceptible</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>127</td><td rowspan=1 colspan=1>96.1%</td><td rowspan=1 colspan=1>91.1 - 98.3%</td></tr><tr><td rowspan=1 colspan=1>Inconclusive</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>17.1%</td><td rowspan=1 colspan=1>8.5 - 31.3%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>131</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>283</td><td rowspan=1 colspan=1>137</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>618</td><td rowspan=1 colspan=1>83.3%</td><td rowspan=1 colspan=1>80.2 - 86.1%</td></tr></table>

Note: Calculations are performed for unshaded areas only.

Comparison of Acute and Non-acute EBV Serological Status   
The results obtained from the summarized information provided in Table 26 were further classified into Acute Infection. Acute Infection includes Primary Acute and Late Acute. Non-Acute Infection includes Susceptible, Recovering and Previous Infection as defined in Table 16. Inconclusive includes any samples reactivity are not consistent with any category listed in Table 16. Results are summarized in Table 26.

Table 26: Acute vs. Non-acute   

<table><tr><td rowspan=2 colspan=2>EBV Serological status</td><td rowspan=1 colspan=6>BioPlex 2200 EBV IgG &amp; IgM Profile</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>Non-te</td><td rowspan=1 colspan=1>ttce</td><td rowspan=1 colspan=1>A</td><td rowspan=1 colspan=1>ooo %Aecn</td><td rowspan=1 colspan=1>Gog %96ieeel</td></tr><tr><td rowspan=4 colspan=1>cAaee</td><td rowspan=1 colspan=1>Acuite</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>141</td><td rowspan=1 colspan=1>88.7%</td><td rowspan=1 colspan=1>82.4 - 92.9%</td></tr><tr><td rowspan=1 colspan=1>Non-Acute</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>394</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>436</td><td rowspan=1 colspan=1>90.4%</td><td rowspan=1 colspan=1>87.2 - 92.8%</td></tr><tr><td rowspan=1 colspan=1>Inconclusive</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>17.1%</td><td rowspan=1 colspan=1>8.5 - 31.3%</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>177</td><td rowspan=1 colspan=1>426</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>618</td><td rowspan=1 colspan=1>85.1%</td><td rowspan=1 colspan=1>82.1 -87.7%</td></tr></table>

Note: Calculations are performed for unshaded areas only.

Comparison of EBV Serological Status (known IgM positive samples) Using Table 16 as a guideline, samples characterized into serological status associated with EBV disease, using the commercially available microplate ElA and agglutination tests, were compared with characterizations using BioPlex 2200 EBV IgG and IgM kits. The BioPlex 2200 EBV IgM kit was run in conjunction with the BioPlex 2200 EBV IgG kit to allow for a complete antibody response profile. The characterization by antibody response was not compared with clinical data regarding presence, absence or status of disease. A total of 100 purchased EBV VCA IgM positive samples were tested at a U.S. clinical testing site. Results are shown in Table 27.

able 27: Comparison of EBV Serological Status (known VCA IgM positive samples   

<table><tr><td rowspan=2 colspan=2>EBV Serological status</td><td rowspan=1 colspan=9>BioPlex 2200 EBV IgG &amp; IgM Profile</td></tr><tr><td rowspan=1 colspan=1>p n</td><td rowspan=1 colspan=1>aeee ee</td><td rowspan=1 colspan=1>Beemm</td><td rowspan=1 colspan=1>Pe od</td><td rowspan=1 colspan=1>Seee</td><td rowspan=1 colspan=1>thctune</td><td rowspan=1 colspan=1>e</td><td rowspan=1 colspan=1>Soon %Are</td><td rowspan=1 colspan=1>Go %96ittea</td></tr><tr><td rowspan=7 colspan=1>AtaesCmcn</td><td rowspan=1 colspan=1>Primary Acute</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Late Acute</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>96.3-100%</td></tr><tr><td rowspan=1 colspan=1>Recovering</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Previous Infection</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Susceptible</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Inconclusive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>96.3-100%</td></tr></table>

Note: Calculations are performed for unshaded areas only.

Comparison of Acute and Non-acute EBV Serological Status (known VCA IgM positive samples) The results obtained from the summarized information provided in Table 27 were further classified into two groups; Acute Infection and Non-Acute Infection. Acute Infection includes Primary Acute and Late Acute. Non-Acute Infection includes samples characterized as Susceptible, Recovering and Previous Infection as defined in Table 16. Inconclusive includes any samples whose patterns of antibody reactivity are not consistent with any category listed in Table 16. Results are summarized in Table 28.

Table 28: Acute vs. Non-acute (known VCA IgM positive samples)   

<table><tr><td rowspan=2 colspan=2>EBV Serological status</td><td rowspan=1 colspan=6>BioPlex 2200 EBV IgG &amp; IgM Profile</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>N-ce</td><td rowspan=1 colspan=1>in</td><td rowspan=1 colspan=1>e</td><td rowspan=1 colspan=1>Sot %Aowann</td><td rowspan=1 colspan=1>So %6ltel</td></tr><tr><td rowspan=4 colspan=1>Pal aeenscY</td><td rowspan=1 colspan=1>Acute</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>96.3-100%</td></tr><tr><td rowspan=1 colspan=1>Non-Acute</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Inconclusive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Overall</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>96.3-100%</td></tr></table>

Note: Calculations are performed for unshaded areas only.

Primary Acute Serological Status by Age   
Theresults rom Table 8 with a Primary Acute serological status were urher analyzed by ge group. Results are summarized in Table 29.

Table 29: Primary Acute Serological Status by Age   

<table><tr><td rowspan=2 colspan=1>EBV Primary AcuteInfection Grouped byAge</td><td rowspan=2 colspan=1>N</td><td rowspan=1 colspan=3>BioPlex 2200 EBV VCA IgM</td><td rowspan=1 colspan=3>BioPlex 2200 Heterophile</td></tr><tr><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>(%)</td><td rowspan=1 colspan=1>95% Cl</td><td rowspan=1 colspan=1>Pos (+)</td><td rowspan=1 colspan=1>(%)</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>&lt;5Yrs</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>51.0 - 100 %</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0%</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>5 - 12 Yrs</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>64.6 - 100 %</td><td rowspan=1 colspan=1>5*</td><td rowspan=1 colspan=1>71%</td><td rowspan=1 colspan=1>35.9 - 91.8%</td></tr><tr><td rowspan=1 colspan=1>13 - 20 Yrs</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>93%</td><td rowspan=1 colspan=1>68.5 - 98.7%</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>71%</td><td rowspan=1 colspan=1>45.4 - 88.3%</td></tr><tr><td rowspan=1 colspan=1>Adult = 21 Yrs</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>61.0 - 100%</td><td rowspan=1 colspan=1>3**</td><td rowspan=1 colspan=1>50%</td><td rowspan=1 colspan=1>18.8 - 81.2%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>83.8 - 99.4%</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>58%</td><td rowspan=1 colspan=1>40.8 - 73.6%</td></tr></table>

Tw () samples were BioPlex 200 positive, commercially available Heterophile Agglutination negative. p  cal ahigt iB

# D. Cross-Reactivity

A cross-reactivity study was performed to determine if samples from various disease states and other potentially interfering factors interfere with test results when tested with the BioPlex 2200 EBV IgM kit. A panel of at least ten (10) specimens\* positive for each cross reactant were evaluated for possible cross reactivity with the BioPlex 2200 EBV IgM kit for both EBV IgM antibody assays. The test specimens were also evaluated on corresponding commercially available microplate EIA and latex agglutination tests. Due to the number of VCA IgM positive results obtained with the initial 10 Toxoplasmosis and CMV samples, an additional 33 toxoplasmosis and 42 CMV positive samples were tested with the BioPlex 2200 EBV IgM kit. This study was performed to demonstrate that the BioPlex 2200 VCA IgM assay does not exhibit cross reactivity with Toxoplasmosis or CMV IgM samples. For these additional samples, only those that exhibited positive reactivity were tested on corresponding commercially available microplate ElA and latex agglutination tests. Most of the samples evaluated were high positive for each disease state. The majority of all samples that elicited a positive result were also confirmed positive by the corresponding commercially available test, indicating reactivity to EBV IgM antibodies rather than cross reactivity with a potentially interfering factor. Results can be found in Table 30.

\*Due to limited availability of samples, only four E. coli specimens were evaluated.

Table 30: Cross-Reactivity   

<table><tr><td rowspan=2 colspan=1>CrossReactives</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Method</td><td rowspan=1 colspan=2>BioPlex 2200EBV IgM</td></tr><tr><td rowspan=1 colspan=1>EEA A</td><td rowspan=1 colspan=1>hec</td></tr><tr><td rowspan=3 colspan=1>ANA</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Commercial Assay</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>Rubella IgM</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Commercial Assay</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>HSV IgM</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Commercial Assay</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>E. Coli</td><td rowspan=3 colspan=1>4*</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Commercial Assay</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=5 colspan=2>Toxo IgM</td><td rowspan=1 colspan=1>BioPlex 2200 (N)</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>43</td></tr><tr><td rowspan=1 colspan=1>BioPlex 2200 (+)</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Commercial Assay (N)</td><td rowspan=1 colspan=1>14+</td><td rowspan=1 colspan=1>10tt</td></tr><tr><td rowspan=1 colspan=1>Cominercial Assay (+)</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td></tr></table>

\*Commercially available assay data was not obtained, due to low sample volume. †Commercially available assay testing was performed on BioPlex 2200 positive samples only. ttCommercially available assay testing was performed on the initial ten samples evaluated.

<table><tr><td rowspan=2 colspan=1>CrossReactives</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>Method</td><td rowspan=1 colspan=2>BioPlex 2200EBV IgM</td></tr><tr><td rowspan=1 colspan=1>EAA AA</td><td rowspan=1 colspan=1>Heoette</td></tr><tr><td rowspan=3 colspan=1>RheumatoidFactor</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Commercial Assay</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>VZV IgM</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Commercial Assay</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=3 colspan=1>HIV</td><td rowspan=3 colspan=1>10*</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Commercial Assay</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>N/A</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=3 colspan=1>Pregnantwomen</td><td rowspan=3 colspan=1>10</td><td rowspan=1 colspan=1>BioPlex 2200</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Commercial Assay</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=5 colspan=2>CMV IgM</td><td rowspan=1 colspan=1>BioPlex 2200 (N)</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>52</td></tr><tr><td rowspan=1 colspan=1>BioPlex 2200 (+)</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Commercial Assay (N)</td><td rowspan=1 colspan=1>25†</td><td rowspan=1 colspan=1>10tt</td></tr><tr><td rowspan=1 colspan=1>Commercial Assay (+)</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Discrepants</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>1</td></tr></table>

Mr. David Bhend Regulatory Affairs Associate Bio-Rad Laboratories, Inc. Diagnostics Group $6 5 6 \bar { 5 } ~ 1 8 5 ^ { \mathrm { t h } }$ Ave, N.E. Redmond, WA 98052

Re: k062213 Trade/Device Name: BioPlex 2200 EBV IgM Panel on the BioPlex 2200 Multi-Analyti Detection System BioPlex 2200 EBV IgM Control Set BioPlex 2200 EBV IgM Calibrator Set Regulation Number: 21 CFR 866.5640 Regulation Name: Infectious mononucleosis immunological test system. Regulatory Class: Class II Product Code: LSE, KTN Dated: November 13, 2006 Received: November 14, 2006

Dear Mr. Bhend:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (MA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150, or at its Internet address   
http://www.fda.gov/cdrh/dsma/dsmamain.html.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and   
Radiological Health

# INDICATIONS FOR USE STATEMENT

510(k) Number: k062213

# Device Name:

BioPlex 2200 EBV IgM Kit on the BioPlex 2200 Multi-Analyte   
Detection System   
BioPlex 2200 EBV IgM Control Set   
BioPlex 2200 EBV IgM Calibrator Set

Indications for Use:

# BioPlex 2200 EBV IgM Kit

The BioPlex 2200 EBV IgM kit is a multiplex flow immunoassay intended for the qualitative detection of two (2) separate analytes; Epstein-Barr Virus Viral Capsid Antigen (EBV VCA) IgM antibodies and Heterophile antibodies in human serum. The test system can be used in conjunction with the BioPlex 2200 EBV IgG kit as an aid in the laboratory diagnosis of infectious mononucleosis (IM).

The EBV IgM kit is intended for use with the Bio-Rad BioPlex 2200 System.

Assay performance characteristics have not been established for immunocompromised or immunosuppressed patients, cord blood, neonatal specimens, or infants. Assay performance characteristics have not been established for the diagnosis of nasopharyngeal carcinoma, Burkitt's lymphoma, and other EBV-associated lymphomas.

# BioPlex 2200 EBV IgM Calibrator Set

The BioPlex 2200 EBV IgM Calibrator Set is intended for the calibration of the BioPlex 2200 EBV IgM Reagent Pack.

# BioPlex 2200 EBV IgM Control Set

The BioPlex 2200 EBV IgM Control Set is intended for use as an assayed quality control to monitor the overall performance of the BioPlex 2200 Instrument and BioPlex 2200 EBV IgM Reagent Pack in the clinical laboratory. The performance of the BioPlex 2200 EBV IgM Control Set has not been established with any other EBV assays.

AND/OR

Prescription Use: _ X (Per 21 CFR 801.109)

Over-The-Counter Use: (Optional Format 1-2-96)